Stock AnalizLabcorp Holdings Inc. LH
Medical Specialities · data as of November 13, 2026
Labcorp Holdings Inc. (LH) is a healthcare company listed in the US with a market value of about $30.1B. In the twelve months to September 30, 2026 it had revenue of $14.6B and net income of $1.0B, a net margin of 6.9%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is shareholder returns (5/5); the weakest is value (0/5).
Key numbers: a P/E of 30.4, a price to free cash flow of 23.4, 5-year revenue growth of -0% a year, a 5-year average ROIC of 8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 14% below the current price.
Score: 2.0 / 5
Checks passed
- Profit margin improving
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6B | $14.0B | $13.0B | $12.2B | $11.9B | $13.1B | $14.0B | $11.6B | $11.3B | $10.3B | $9.6B |
| Net income | $1.0B | $876M | $746M | $418M | $1.3B | $2.4B | $1.6B | $824M | $884M | $1.2B | $712M |
| Free cash flow | $1.3B | $1.2B | $1.1B | $874M | $1.5B | $2.7B | $1.8B | $1.0B | $926M | $1.2B | $918M |
| EPS (diluted) | $12.19 | $10.46 | $8.84 | $4.77 | $13.97 | $24.39 | $15.88 | $8.35 | $8.61 | $11.81 | $6.82 |
| Net margin | 6.9% | 6.3% | 5.7% | 3.4% | 10.8% | 18.1% | 11.1% | 7.1% | 7.8% | 11.9% | 7.4% |
| ROIC | — | 7.2% | 5.6% | 4.2% | 7.0% | 14.6% | 12.0% | 7.2% | 8.0% | 7.6% | 8.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $390.06, 5% above the current price; targets range from $347.00 to $420.00; the consensus rating is “Buy”; expected EPS is $18.49 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Labcorp’s P/E ratio?
About 30.4, based on the last twelve months of diluted earnings per share (forward P/E about 19.7).
Is Labcorp stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 14% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Labcorp pay a dividend?
Yes. The dividend yield is about 0.77%, and it has paid dividends for 4 years in our data.
Is Labcorp a good stock to buy?
We do not give buy or sell advice. Labcorp scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.